OBI forfeits subscription of AP Biosciences' cash
capital increase, distributes rights to its shareholders
and sets target date
Date of events
2022/08/08
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/08/08
2.Company name:OBI Pharma Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:To be conducted by the Board of Directors' resolution
on 2022/08/08.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)The Company decides to forfeit all the preemptive rights of AP
Biosciences' cash capital increase and distribute the rights to
shareholders of OBI. The issue price is expected to be NT$50 per share,
with each thousand shares of OBI bearing the subscription rights for
34.3016 shares of AP Biosciences. The forfeiture is approved by the
Company's Board of Directors on 2022/08/08.
(2)To coordinate with AP Bioscience' schedule of the reference date of
cash capital increase, the reference date for shareholders of OBI to
subscribe the new shares is announced as follows:
A.The target date of distribution of other benefits of the Company:
2022/08/28
B.The book closure period of the Company:2022/08/24~2022/08/28
C.Last date before book closure of the Company:2022/08/23
D.Ex-rights date of the Company:2022/08/22
E.Payment period of the Company:2022/08/30~2022/09/06
The subscription rights may not be transferred. Once the period of
existence expires, shareholders may no longer claim his or her
subscription rights to subscribe for shares.
F.The reference date of cash capital increase of AP Bioscience:
2022/10/4 (tentatively)
(3)To coordinate with stock affairs of AP Bioscience, share subscription
form will be sent through registered mail to shareholders whose
available shares based on the shareholding ratio stated on the register
of shareholders on the book closure date exceed one thousand shares.
Other shareholders whose available shares are less than one thousand
shares will be notified only by announcement. For shareholders who do
not receive the share subscription form, please contact transfer agent
of AP Biosciences for payment information.
Masterlink Securities
TEL:(02)2768-6668
Address:B1., No. 35, Ln. 11, Guangfu N. Rd., Songshan Dist.,
Taipei City, Taiwan.
(4)The Chairman was authorized to decide change of the schedule, or any
other matters not covered herein.
Attachments
Original Link
Original Document
Permalink
Disclaimer
OBI Pharma Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 08:43:08 UTC.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
OBI PHARMA, INC. 
